8 treatment recommendations for PsA

Mar 18, 2019

In this slideshow, we address the treatment recommendations for adults with active psoriatic arthritis despite previous treatment with biologics.

The January issue of Arthritis and Rheumatology includes updated treatment guidelines for adults with active psoriatic arthritis (PsA). The guidelines, by the American College of Rheumatology and the National Psoriasis Foundation, address how best to prescribe oral small molecules, tumor necrosis factor inhibitors, IL-12/23i inhibitors, IL-17 inhibitors, CTLA4-Ig (abatacept) and the JAK inhibitor tofacitinib.In this slideshow, we address the treatment recommendations for adults with active psoriatic arthritis despite previous treatment with biologics.

References:

Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al. "American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis," Arthritis and Rheumatology. January 2019. DOI 10.1002/art.40726